M. Lindzen

发表

AhR controls redox homeostasis and shapes the tumor microenvironment in BRCA1-associated breast cancer

D. Cescon, T. Mak, M. Pujana, 2019, Proceedings of the National Academy of Sciences.

Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR

Y. Yarden, M. Sela, Z. Porat, 2013, Proceedings of the National Academy of Sciences.

An antibody to amphiregulin, an abundant growth factor in patients’ fluids, inhibits ovarian tumors

G. Mills, I. Barshack, Y. Yarden, 2016, Oncogene.

Nucleoporin-93 reveals a common feature of aggressive breast cancers: robust nucleocytoplasmic transport of transcription factors.

A. Ciechanover, E. Ruppin, C. Caldas, 2022, Cell reports.

Database-independent Protein Sequencing (DiPS) Enables Full-length de Novo Protein and Antibody Sequence Determination *

Y. Yarden, Y. Levin, A. Savidor, 2017, Molecular & Cellular Proteomics.

Nucleoporin-93 overexpression overcomes multiple nucleocytoplsamic trafficking bottlenecks to permit robust metastasis

A. Ciechanover, E. Ruppin, C. Caldas, 2020 .

Edinburgh Research Explorer AhR controls redox homeostasis and shapes the tumour microenvironment in BRCA1-associated breast cancer

D. Cescon, T. Mak, M. Pujana, 2019 .

Targeting autocrine amphiregulin robustly and reproducibly inhibits ovarian cancer in a syngeneic model: roles for wildtype p53

Y. Yarden, I. McNeish, Soma Ghosh, 2021, Oncogene.

Epigenetic mechanisms underlie the crosstalk between growth factors and a steroid hormone

S. Wiemann, M. Szyf, M. Feldman, 2017, Nucleic acids research.

PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR

E. Ruppin, B. Geiger, S. Weiss, 2021, Cell reports.

Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer

S. Wiemann, C. Caldas, R. Russell, 2015, Science Signaling.

A reciprocal tensin-3–cten switch mediates EGF-driven mammary cell migration

I. Amit, A. Citri, S. Lo, 2007, Nature Cell Biology.

AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer

A. Regev, E. Ruppin, S. Wiemann, 2022, Cancer discovery.

Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models

T. Salame, Y. Yarden, Diana Drago-Garcia, 2021, EMBO molecular medicine.

Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor

Y. Yarden, L. Paz-Ares, E. Pikarsky, 2020, Cancers.

A Novel Role for the Interleukin-1 Receptor Axis in Resistance to Anti-EGFR Therapy

B. Győrffy, Y. Yarden, A. Ardizzoni, 2018, Cancers.

A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors

Y. Yarden, P. Lollini, L. Trusolino, 2016, Oncotarget.

An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors

T. Salame, Y. Yarden, J. Downward, 2017, EMBO molecular medicine.

SILAC identifies LAD1 as a filamin-binding regulator of actin dynamics in response to EGF and a marker of aggressive breast tumors

Michal Sheffer, C. Caldas, O. Rueda, 2018, Science Signaling.

Host-Dependent Phenotypic Resistance to EGFR Tyrosine Kinase Inhibitors

S. Wiemann, Y. Yarden, Diana Drago-Garcia, 2021, Cancer Research.

Bortezomib‐induced pro‐inflammatory macrophages as a potential factor limiting anti‐tumour efficacy

Y. Yarden, V. Miller, Y. Shaked, 2016, The Journal of pathology.

A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways

T. Salame, Y. Yarden, A. Onn, 2018, Clinical Cancer Research.

Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3

Y. Yarden, N. Gaborit, M. Lindzen, 2016, Human vaccines & immunotherapeutics.

Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer

Y. Yarden, J. Downward, Maicol Mancini, 2015, Science Signaling.

Functional Interactions of Phospholemman (PLM) (FXYD1) with Na+,K+-ATPase

H. Garty, S. Karlish, M. Lindzen, 2006, Journal of Biological Chemistry.

Structural Interactions between FXYD Proteins and Na+,K+-ATPase

K. Gottschalk, H. Garty, S. Karlish, 2006, Journal of Biological Chemistry.

Covalent Cross-links between the γ Subunit (FXYD2) and α and β Subunits of Na,K-ATPase

B. Küster, K. Gottschalk, H. Garty, 2005, Journal of Biological Chemistry.

Diurnal suppression of EGFR signalling by glucocorticoids and implications for tumour progression and treatment

Eytan Domany, Stefan Wiemann, Yehoshua Enuka, 2014, Nature Communications.

LAD 1 as a filamin-binding regulator of actin dynamics in response to EGF and a marker of aggressive breast tumors

Michal Sheffer, C. Caldas, O. Rueda, 2018 .

Examination of HER3 targeting in cancer using monoclonal antibodies

Y. Yarden, M. Sela, H. Bazin, 2015, Proceedings of the National Academy of Sciences.

O ncogenic receptor tyrosine kinases : Implications for cancer progression and therapy

G. Tarcic, G. Pines, Yaron Mosesson, 2022 .

A functional interaction between CHIF and Na-K-ATPase: implication for regulation by FXYD proteins.

N. Farman, H. Garty, S. Karlish, 2002, American journal of physiology. Renal physiology.

A recombinant decoy comprising EGFR and ErbB-4 inhibits tumor growth and metastasis

Y. Yarden, S. Bacus, S. Lavi, 2011, Oncogene.

Tailored cancer immunotherapy using combinations of chemotherapy and a mixture of antibodies against EGF-receptor ligands

Y. Yarden, S. Lavi, O. Leitner, 2010, Proceedings of the National Academy of Sciences.

Polyclonal antibody-induced downregulation of HER1/EGFR and HER2 surpasses the effect of combinations of specific registered antibodies

Y. Yarden, M. Lindzen, B. Sánchez-Ramírez, 2022, Frontiers in Oncology.